Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.68 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.68 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.68 |
| ▸ | TSHR | P16473 | 1/20 | 0.68 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.68 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.62 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.62 |
| ▸ | NPC1 | O15118 | 1/20 | 0.61 |
| ▸ | RAB9A | P51151 | 1/20 | 0.61 |
| ▸ | FLT3 | P36888 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7065908 | 0.87 | HDAC6 (0.69) | MEN1KMT2ACYP1A2CYP3A4CYP2C9 | |
| SCHEMBL6389792 | 0.85 | MEN1 (0.82) | MEN1KMT2ACYP1A2CYP3A4CYP2C9 | |
| SCHEMBL6171445 | 0.82 | MEN1 (0.76) | MEN1KMT2ACYP1A2CYP3A4CYP2C9 | |
| SCHEMBL5828518 | 0.81 | MEN1 (1.00) | MEN1KMT2ACYP1A2CYP3A4CYP2C9 | |
| SCHEMBL29354248 | 0.81 | MEN1 (1.00) | MEN1KMT2ACYP1A2CYP3A4CYP2C9 | |
| SCHEMBL7066250 | 0.81 | MEN1 (0.74) | MEN1KMT2ACYP1A2CYP3A4CYP2C9 | |
| SCHEMBL6395923 | 0.79 | HDAC6 (0.84) | MEN1KMT2ACYP1A2CYP3A4CYP2C9 | |
| SCHEMBL7789143 | 0.79 | MAPT (0.64) | MEN1KMT2ATSHRNPC1RAB9A | |
| SCHEMBL7063661 | 0.79 | PDGFRB (0.61) | MEN1KMT2ACYP1A2CYP3A4CYP2C9 | |
| SCHEMBL7066038 | 0.79 | PDGFRB (0.61) | MEN1KMT2ACYP1A2CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030158216-A1 | 2-acyl indole derivatives and their use as antitumor agents | BAXTER ONCOLOGY GMBH | 2003-08-21 | — | — | US | disclosed |
| US-20020091124-A1 | 2-acyl indole derivatives and their use as antitumor agents | BECKERS THOMAS (DE) | 2002-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030158216-A1 | 2-acyl indole derivatives and their use as antitumor agents | IDO1, IDO2, INMT | MEN1 1405/4885KMT2A 554/4885CYP1A2 469/4885 |
| US-20020091124-A1 | 2-acyl indole derivatives and their use as antitumor agents | IDO1, IDO2, INMT | MEN1 1405/4885KMT2A 554/4885CYP1A2 469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.